학술논문
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
Document Type
Report
Author
Bassi, Jessica; Giannini, Olivier; Silacci-Fregni, Chiara; Pertusini, Laura; Hitz, Paolo; Terrot, Tatiana; Franzosi, Yves; Muoio, Francesco; Saliba, Christian; Meury, Marcel; Dellota, Exequiel A.; Dillen, Josh R.; Hernandez, Patrick; Czudnochowski, Nadine; Cameroni, Elisabetta; Beria, Nicola; Ventresca, Mariangela; Badellino, Alberto; Lavorato-Hadjeres, Soraya; Lecchi, Elisabetta; Bonora, Tecla; Mattiolo, Matteo; Trinci, Guido; Garzoni, Daniela; Bonforte, Giuseppe; Forni-Ogna, Valentina; Giunzioni, Davide; Berwert, Lorenzo; Gupta, Ravindra K.; Ferrari, Paolo; Ceschi, Alessandro; Cippà, Pietro; Corti, Davide; Lanzavecchia, Antonio; Piccoli, Luca
Source
PLoS ONE. February 10, 2022, Vol. 17 Issue 2, e0263328
Subject
Language
English
ISSN
1932-6203
Abstract
Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy.
Author(s): Jessica Bassi 1, Olivier Giannini 2,3, Chiara Silacci-Fregni 1, Laura Pertusini 4, Paolo Hitz 2, Tatiana Terrot 5, Yves Franzosi 5, Francesco Muoio 1, Christian Saliba 1, Marcel Meury [...]
Author(s): Jessica Bassi 1, Olivier Giannini 2,3, Chiara Silacci-Fregni 1, Laura Pertusini 4, Paolo Hitz 2, Tatiana Terrot 5, Yves Franzosi 5, Francesco Muoio 1, Christian Saliba 1, Marcel Meury [...]